FDA OKs First ' Extended ' Adjuvant Treatment for HER2 Breast Cancer FDA OKs First ' Extended ' Adjuvant Treatment for HER2 Breast Cancer

The FDA has approved a new drug for patients with early-stage HER2-positive breast cancer who have completed trastuzumab and want"extended" adjuvant therapy.FDA Approvals

Source: Medscape Medical News Headlines - July 17, 2017 Category: Consumer Health News Tags: Hematology-Oncology News Alert Source Type: news